Rasuvo is an anti-rheumatic drug owned by Medexus. It contains methotrexate as its active ingredient and was first authorized for market use on 10 July, 2014. The drug is available in the form of a subcutaneous injection solution.
The generic versions of Rasuvo are expected to be released after 01 June, 2029. The last patent, US8664231 - titled 'Concentrated methotrexate solutions', expires on this date, paving the way for the introduction of Rasuvo generics in the market.
Rasuvo, with methotrexate as its primary ingredient, is commonly used to treat certain types of cancer or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. The methotrexate in the solution interferes with the growth of certain cells in the body, particularly those that rapidly reproduce, such as cancer cells, skin cells, and bone marrow cells.
Rasuvo, owned by Medexus, has a total of 1 drug patent. The last patent - US8664231, titled 'Concentrated methotrexate solutions' - is expected to expire on 01 June, 2029. Therefore, the release of Rasuvo generics is anticipated after this date. Below are the details of the patent: